olmesartan medoxomil has been researched along with Albuminuria in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, TX; Ding, A; Li, ZL; Yang, H; Zhang, H; Zhang, HT; Zhu, WP; Zhu, Y | 1 |
| Chin, HJ; Choi, BS; Kim, DK; Lee, SH; Lim, CS; Park, JH; Shin, SJ; Yu, MY | 1 |
| Chatzikyrkou, C; Haller, H; Menne, J; Ritz, E; Ruilope, LM; Viberti, G | 1 |
| Kaul, U; Mansoor, A; Sabbah, ZA | 1 |
| An, JN; Chin, HJ; Choi, BS; Hwang, JH; Kim, DK; Kim, S; Lee, JP; Lee, SH; Lim, CS; Park, JH; Shin, SJ | 1 |
| Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Yoshida, K; Yoshiyama, M | 1 |
3 trial(s) available for olmesartan medoxomil and Albuminuria
| Article | Year |
|---|---|
Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients.
Topics: Aged; Albuminuria; Angiotensin II Type 2 Receptor Blockers; Area Under Curve; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Olmesartan Medoxomil; Renal Insufficiency, Chronic; Risk Factors; ROC Curve | 2018 |
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Imidazoles; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Olmesartan Medoxomil; Proportional Hazards Models; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2014 |
The Decrement of Hemoglobin Concentration with Angiotensin II Receptor Blocker Treatment Is Correlated with the Reduction of Albuminuria in Non-Diabetic Hypertensive Patients: Post-Hoc Analysis of ESPECIAL Trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Case-Control Studies; Erythropoietin; Female; Hemoglobins; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Receptors, Angiotensin; Renin-Angiotensin System; Treatment Outcome | 2015 |
3 other study(ies) available for olmesartan medoxomil and Albuminuria
| Article | Year |
|---|---|
Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Male; Mice; Olmesartan Medoxomil | 2019 |
Angiotensin receptor blockers - advantages of the new sartans.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Telmisartan; Tetrazoles; Treatment Outcome | 2013 |
Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiac Output, Low; Creatinine; Dihydropyridines; Drug Combinations; Echocardiography; Gene Expression; Hypertension; Imidazoles; Myocardium; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred Dahl; Survival Analysis; Tetrazoles; Thiazepines | 2004 |